Miranda Jayne Toledano - Sep 13, 2023 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Executive Officer, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol: ENTX
Transactions as of: Sep 13, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/14/2023, 05:02 PM
Previous filing: Aug 21, 2023
Next filing: Dec 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTX	Stock Option (right to buy)	Award	$0	+350K		$0.00	350K	Sep 13, 2023	Ordinary Shares, par value NIS 0.0000769 per share	350K	$0.80	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 24, 2023, subject to approval by the Company's shareholders, which was obtained on September 13, 2023. The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

Content

This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 24, 2023, subject to approval by the Company's shareholders, which was obtained on September 13, 2023. The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.